Tetanus, Diphtheria and Polio Combined Vaccine: Td POLIO
Biological Page

Section 7: Biological Product Information
Standard #: 07.321

Created by: Province-wide Immunization Program, Standards and Quality
Approved by: Province-wide Immunization Program, Standards and Quality
Approval Date: June 1, 2015
Revised: February 1, 2017

Td POLIO ADSORBED

Manufacturer: Sanofi Pasteur Limited

Biological Classification: Tetanus and Diphtheria Toxoids Adsorbed and Inactivated Poliomyelitis Vaccine

Indications for Provincially Funded Vaccine

Adults - 18 years of age and older:

- When immunization for tetanus, diphtheria and polio is indicated (primary or reinforcing doses). Refer to the Scheduling Section.

Notes:

- A primary series with Td Polio vaccine is indicated for adults who are at increased risk of exposure to polio virus (see below) who have never started/completed a primary immunization series for tetanus, diphtheria and polio.
- Due to the limited supply of polio vaccine and the low risk of exposure to polio in Alberta and Canada – the recommendation for the routine immunization of unimmunized adults who are not at risk for exposure to polio virus is suspended until further notice.
- Adults at high/increased risk of exposure to polio (as outlined below) who have completed their primary tetanus and diphtheria immunization should be offered a reinforcing dose of polio vaccine at 18 years of age and older. This reinforcing dose of polio can be given as combined tetanus, diphtheria, polio vaccine or combined tetanus, diphtheria, pertussis, polio vaccine if they are due for tetanus, diphtheria or pertussis reinforcing dose or as single antigen polio if they are not due for a reinforcing dose of tetanus, diphtheria or pertussis.
- Adult recipients of hematopoietic stem cell transplantation (HSCT) and candidates / recipients of solid organ transplant (SOT). See Standard for the Immunization of Transplant Candidates and Recipients for recommended vaccine and schedules.
- Adults who sustain a tetanus prone wound need to have their tetanus immunization history assessed (see Tetanus Prophylaxis, Prevention and Wound/Injury Management Standard).

Groups at High/Increased Risk of Exposure to Polio:

Adults in the following groups are at increased risk of exposure to poliovirus and should receive a primary series:

- Health care workers (HCW) providing direct patient care who may be exposed to patients excreting the wild or vaccine strains of polio virus (contact with stool or fecal matter).
- Laboratory workers handling specimens that may contain poliovirus.
- Members of communities or specific population groups with disease caused by polio.
- Close contact with those who may be excreting poliovirus (e.g. people working with refugees or people on humanitarian missions in countries where polio is circulating - exporting and/or infected).
- Family members or close contacts of internationally adopted infants who may have been immunized with OPV vaccine.

Note:

For questions related to Travel and or For Sale vaccine refer to AHS Travel Health and Contracted Immunization Services resources.
### Td POLIO ADSORBED

- Individuals receiving travelers from areas where poliovirus is known to be circulating.
- Adults travelling for 4 weeks or greater to countries currently exporting and/or infected with polio.

**Notes:**
- Individuals travelling to countries currently exporting and/or infected with polio may need special immunization documentation verifying polio immunization. These individuals should consult with a Travel Clinic to determine what documentation is required.

#### Schedule

**Primary series:**
- Dose 1: day 0
- Dose 2: 8 weeks after dose 1 (interval between doses may be shortened to four weeks)
- Dose 3: 6 – 12 months after dose 2

**Note:**
Adults receiving a primary series of Td Polio should receive dTap-IPV as the first dose in the series.

**Reinforcing vaccine dose:**
- One lifetime dose of polio-containing vaccine in adulthood (after 18th birthday) for those at increased risk of exposure to polio (see Indications Section for description of groups at high/increased risk of exposure to polio.).

**Note:**
Unless at increased risk of exposure to polio, reinforcing doses of polio-containing vaccine are not routinely recommended for adults living in Canada.

#### Preferred Use

NA

#### Dose

0.5 mL

#### Route

IM

#### Contraindications/Precautions

**Contraindications:**
- Known severe hypersensitivity to any component of Td POLIO ADSORBED
- Anaphylactic or other allergic reaction to a previous dose of vaccine containing tetanus, diphtheria or polio antigens.

**Precautions:**
- If Guillain-Barré Syndrome (GBS) occurred within six weeks of immunization with a previous dose of vaccine containing tetanus toxoid, it is prudent to withhold subsequent doses of tetanus-containing vaccine. Those who develop GBS outside this interval may receive subsequent doses of tetanus toxoid-containing vaccine. If there is a history of both Campylobacter infection and receipt of a tetanus-containing vaccine within six weeks before the onset of GBS, consultation with an infectious disease specialist is advised.

#### Possible Reactions

**Common side effects include:**
- Tenderness, redness, itchiness and swelling at the injection site
- Following reinforcing doses, local erythema and swelling
- Headache, dizziness, malaise and rash

**Rare side effects include:**
- Persistent nodule at the site of injection
**Td POLIO ADSORBED**

- Arthus-type of hypersensitivity characterized by a severe local reaction, generally starting 2 to 8 hours after injection. Such reaction may be associated with high levels of circulating antitoxin in persons with frequent injections of tetanus toxoid.
- Arthralgia, myalgia, lymphadenopathy, convulsions, headache transient and mild paresthesia, agitation, somnolence, irritability, rash and urticarial.
- As with any immunization, unexpected or unusual side effects can occur. Refer to the product monograph for more detailed information.

**Pregnancy**

Adequate data is not available for the use of Td Polio vaccine during pregnancy and therefore will not routinely be recommended in Alberta for pregnant women. However, use of this vaccine during pregnancy may be considered in consultation with your MOH based on the individual’s risk of disease versus benefit of the vaccine.

**Lactation**

Can be administered to eligible breastfeeding women.

**Composition**

Each 0.5ml dose of Td Polio ADSORBED contains:

**Active Ingredients**-
- 5 Lf tetanus toxoid
- 2 Lf diphtheria toxoid
- purified inactivated poliomyelitis vaccine
  - Type 1 (Mahoney) 40 D-antigen units
  - Type 2 (MEF1) 8 D-antigen units
  - Type 3 (Saukett) 32 D-antigen units

**Non-medical Ingredients**-
- 2-phenoxyethanol
- aluminum phosphate (adjuvant)
- isotonic solution of sodium chloride in water for injection.

**Manufacturing residuals include trace amounts of** -
- formaldehyde
- polysorbate 80
- bovine serum albumin
- neomycin and polymyxin B

**Blood/Blood Products**

Does not contain human blood or blood products.

**Bovine/Porcine Products**

Bovine-derived products may be present in small amounts either as components of the culture media used to manufacture the vaccine or as a component of the final vaccine.

**Latex**

The stopper of the vial for this product does not contain dry natural latex rubber.

**Interchangeability**

Individuals who begin their immunization with a different combined product may complete immunization using Td Polio as appropriate for indication and age.

**Administration with Other Products**

- May be given at the same time as other inactivated vaccine, using a separate needle and syringe for each vaccine.
- The same limb may be used if necessary, but different sites on the limb must be chosen.

**Appearance**

- Sterile, cloudy, white, uniform suspension
- Shake well to uniformly distribute the suspension before withdrawing the dose.

**Storage**

- Store at +2° to +8°C
- Do not freeze
- Do not use beyond the labeled expiry date
<table>
<thead>
<tr>
<th><strong>Td POLIO ADSORBED</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>• Store in original packaging when possible to protect from light</td>
</tr>
</tbody>
</table>

| **Vaccine Code** | Td-IPV |
| **Antigen Code** | T- Tetanus Toxoid, D-Diphtheria Toxoid, POL- Polio (inactivated) |
| **Licensed for** | Individuals 7 years of age and older. No off license use is approved in Alberta. |

**Notes:**
Td Polio vaccine has been used sporadically throughout Alberta since 1984. It was re-introduced into the Alberta immunization program June 1, 2015.

**Related Documents:**
• Td Polio Vaccine Information Sheet (July 1, 2015)

**References:**